J. Jonklaas, A.C. Bianco, A.J. Bauer, K.D. Burman, A.R. Cappola et al., Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24, 1670–1751 (2014).

Google Scholar 

G.J. Canaris, N.R. Manowitz, G. Mayor, E.C. Ridgway, The Colorado thyroid disease prevalence study. Arch. Intern. Med. 160, 526–534 (2000).

CAS  Google Scholar 

D.S. Cooper, B. Biondi, Subclinical thyroid disease. Lancet 379, 1142–1154 (2012).

Google Scholar 

ClinCalc DrugStats Database: The Top 200 Drugs of 2022. https://clincalc.com/Drugstats/. Accessed 5/28/2025.

J.P. Brito, J.S. Ross, O.M. El Kawkgi, S. Maraka, Y. Deng et al., Levothyroxine Use in the United States, 2008-2018. JAMA Intern. Med. 181, 1402–1405 (2021).

CAS  Google Scholar 

P.N. Taylor, A. Iqbal, C. Minassian, A. Sayers, M.S. Draman et al., Falling threshold for treatment of borderline elevated thyrotropin levels-balancing benefits and risks: evidence from a large community-based study. JAMA Intern. Med. 174, 32–39 (2014).

CAS  Google Scholar 

J. Meyerovitch, P. Rotman-Pikielny, M. Sherf, E. Battat, Y. Levy et al., Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. Arch. Intern. Med. 167, 1533–1538 (2007).

CAS  Google Scholar 

E. van der Spoel, N.A. van Vliet, R.K.E. Poortvliet, R.S. Du Puy, W.P.J. den Elzen et al., Incidence and determinants of spontaneous normalization of subclinical hypothyroidism in older adults. J. Clin. Endocrinol. Metab. 109, e1167–e1174 (2024).

Google Scholar 

M. Feller, M. Snel, E. Moutzouri, D.C. Bauer, M. de Montmollin et al., Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA 320, 1349–1359 (2018).

CAS  Google Scholar 

J. Ravensberg, R.K.E. Poortvliet, R. Du Puy, N. Rodondi, M. Blum et al., Patient-reported satisfaction with thyroid hormone replacement therapy for subclinical hypothyroidism in older adults: a pooled analysis of individual participant data from two randomized controlled trials. Thyroid 34, 702–712 (2024).

CAS  Google Scholar 

G.E. Bekkering, T. Agoritsas, L. Lytvyn, A.F. Heen, M. Feller et al., Thyroid hormones treatment for subclinical hypothyroidism: a clinical practice guideline. BMJ 365, l2006 (2019).

CAS  Google Scholar 

N. Burgos, F.J.K. Toloza, N.M. Singh Ospina, J.P. Brito, R.G. Salloum et al., Clinical outcomes after discontinuation of thyroid hormone replacement: a systematic review and meta-analysis. Thyroid 31, 740–751 (2021).

CAS  Google Scholar 

T.R. Radomski, A. Decker, D. Khodyakov, C.T. Thorpe, J.T. Hanlon et al., Development of a metric to detect and decrease low-value prescribing in older adults. JAMA Netw. Open. 5, e2148599–e2148599 (2022).

Google Scholar 

K. Anderson, D. Stowasser, C. Freeman, I. Scott, Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 4, e006544 (2014).

Google Scholar 

J. Bolt, R. Abdoulrezzak, C. Inglis, Barriers and enablers to deprescribing of older adults and their caregivers: a systematic review and meta-synthesis. Eur. Geriatr. Med. 14, 1211–1222 (2023).

Google Scholar 

L. Brunner, N. Rodondi, C.E. Aubert, Barriers and facilitators to deprescribing of cardiovascular medications: a systematic review. BMJ Open. 12, e061686 (2022).

Google Scholar 

A.J. Doherty, P. Boland, J. Reed, A.J. Clegg, A.M. Stephani et al., Barriers and facilitators to deprescribing in primary care: a systematic review. BJGP Open. 4, bjgpopen20X101096 (2020).

Google Scholar 

M. Mellot, L. Jawal, T. Morel, J.P. Fournier, F. Tubach et al., Barriers and enablers for deprescribing glucose-lowering treatment in older adults: a systematic review. J. Am. Med. Dir. Assoc. 25, 439–447.e418 (2024).

Google Scholar 

D.A. Okeowo, S.T.R. Zaidi, B. Fylan, D.P. Alldred, Barriers and facilitators of implementing proactive deprescribing within primary care: a systematic review. Int. J. Pharm. Pract. 31, 126–152 (2023).

Google Scholar 

M. Seewoodharry, K. Khunti, M.J. Davies, C. Gillies, S. Seidu, Attitudes of older adults and their carers towards de-prescribing: a systematic review. Diabet. Med. 39, e14801 (2022).

Google Scholar 

B. Moretti, R. Livecchi, S.R. Taylor, S.C. Pitt, B.L. Gay et al., Physician-reported barriers and facilitators to thyroid hormone deprescribing in older adults. J. Am. Geriatr. Soc. 73, 566–573 (2024).

Google Scholar 

J.R. Garber, R.H. Cobin, H. Gharib, J.V. Hennessey, I. Klein et al., Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Thyroid 22, 1200–1235 (2012).

CAS  Google Scholar 

F. Hajtalebi, F. Alaei-Shahmiri, F. Golgiri, N. Shahini, H. Akbari et al., Early effects of LT3 + LT4 combination therapy on quality of life in hypothyroid patients: a randomized, double-blind, parallel-group comparison trial. BMC Endocr. Disord. 25, 22 (2025).

CAS  Google Scholar 

S. Livadas, N. Angelopoulos, A. Kollias, R.D. Paparodis, I. Androulakis et al., Thyroxine overuse and clinical indices guiding successful treatment withdrawal. J. Endocrinol. Invest. 48, 1139–1147 (2025).

CAS  Google Scholar 

E.R. Garnett, J.V. Pagaduan, S. Devaraj, Trust your endocrinologist - report and recommendations on the ordering of reverse T3 testing. Ann. Clin. Lab. Sci. 50, 383–385 (2020).

Google Scholar 

R.B. Haynes, D.W. Taylor, D.L. Sackett, E.S. Gibson, C.D. Bernholz et al., Can simple clinical measurements detect patient noncompliance?. Hypertension 2, 757–764 (1980).

CAS  Google Scholar 

T. Watt, L. Hegedus, M. Groenvold, J.B. Bjorner, A.K. Rasmussen et al., Validity and reliability of the novel thyroid-specific quality of life questionnaire, ThyPRO. Eur. J. Endocrinol. 162, 161–167 (2010).

CAS  Google Scholar 

C.K. Wong, B.H. Lang, C.L. Lam, A systematic review of quality of thyroid-specific health-related quality-of-life instruments recommends ThyPRO for patients with benign thyroid diseases. J. Clin. Epidemiol. 78, 63–72 (2016).

Google Scholar 

G. EuroQol, EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16, 199–208 (1990).

Google Scholar 

T. Watt, J.B. Bjorner, M. Groenvold, P. Cramon, K.H. Winther et al., Development of a short version of the thyroid-related patient-reported outcome ThyPRO. Thyroid 25, 1069–1079 (2015).

Google Scholar 

D.J. Stott, N. Rodondi, P.M. Kearney, I. Ford, R.G.J. Westendorp et al., Thyroid hormone therapy for older adults with subclinical hypothyroidism. N. Engl. J. Med. 376, 2534–2544 (2017).

CAS  Google Scholar 

B.H. Chang, A.M. Hendricks, M.T. Slawsky, J.S. Locastro, Patient recruitment to a randomized clinical trial of behavioral therapy for chronic heart failure. BMC Med. Res. Methodol. 4, 8 (2004).

Google Scholar 

K.M. Harrington, X.T. Nguyen, R.J. Song, K. Hannagan, R. Quaden et al., Gender differences in demographic and health characteristics of the million Veteran Program Cohort. Womens Health Issues 29, S56–S66 (2019).

Google Scholar 

T.E. Strayer, E.K. Hollingsworth, A.S. Shah, E.E. Vasilevskis, S.F. Simmons et al., Why do older adults decline participation in research? results from two deprescribing clinical trials. Trials 24, 456 (2023).

Google Scholar 

M. de Montmollin, M. Feller, S. Beglinger, A. McConnachie, D. Aujesky et al., L-thyroxine therapy for older adults with subclinical hypothyroidism and hypothyroid symptoms: secondary analysis of a randomized trial. Ann. Intern. Med. 172, 709–716 (2020).

Google Scholar 

F.J.K. Toloza, O.M. El Kawkgi, H.J. Spencer, S.E. Mathews, A. Garcia et al., Determinants for thyroid hormone replacement therapy in subclinical hypothyroidism: a multicenter electronic health records-based study. Thyroid 33, 1045–1054 (2023).

CAS  Google Scholar 

J.J. Diez, P. Iglesias, Spontaneous subclinical hypothyroidism in patients older than 55 years: an analysis of natural course and risk factors for the development of overt thyroid failure. J. Clin. Endocrinol. Metab. 89, 4890–4897 (2004).

CAS  Google Scholar 

F.R. Ernst, P. Barr, R. Elmor, W. Sandulli, L. Thevathasan et al., The Economic impact of levothyroxine dose adjustments: the CONTROL HE Study. Clin. Drug. Investig. 37, 71–83 (2017).

CAS  Google Scholar 

M.E. Johansen, J.P. Marcinek, J. Doo Young Yun, Thyroid hormone use in the United States, 1997–2016. J. Am. Board. Fam. Med. 33, 284–288 (2020).

Google Scholar 

F.J.K. Toloza, S.E. Theriot, N.M. Singh Ospina, S. Nooruddin, B. Keathley et al., Knowledge, attitudes, beliefs, and treatment burden related to the use of levothyroxine in hypothyroid pregnant women in the United States. Thyroid 31, 669–677 (2021).

CAS  Google Scholar 

R.W. Flynn, S.R. Bonellie, R.T. Jung, T.M. MacDonald, A.D. Morris et al., Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J. Clin. Endocrinol. Metab. 95, 186–193 (2010).

CAS  Google Scholar 

CHARTBOOK ON HEALTHCARE FOR VETERANS-National Healthcare Quality and Disparities Report, (2020), https://www.ncbi.nlm.nih.gov/books/NBK578546/pdf/Bookshelf_NBK578546.pdf. Accessed 28 May 2025

A. Terlea, F.J.K. Toloza, R.R. Owen, J.S. Williams, M. Knox et al., Frequency and determinants of levothyroxine therapy initiation for veterans with subclinical hypothyroidism. J. Clin. Med. 13, 5727 (2024).

CAS  Google Scholar